Products for Research Use Only

Falecalcitriol

CAT: 0804-HY-32342-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-32342-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Falecalcitriol (Fulstan; Hornel) is an analog of calcitriol; has a higher potency both in vivo and in vitro systems, and longer duration of action in vivo.
CAS Number
83805-11-2
UNSPSC
12352211
Hazard Statement
H302, H315, H319, H335
Target
VD/VDR
Type
Reference compound
Related Pathways
Vitamin D Related/Nuclear Receptor
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/falecalcitriol.html
Purity
98.72
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
C[C@]([C@]/12[H])([C@H](CC2)[C@@H](CCCC(C(F)(F)F)(C(F)(F)F)O)C)CCCC1=C/C=C(C[C@@H](O)C[C@@H]3O)\C3=C
Molecular Formula
C27H38F6O3
Molecular Weight
524.58
Precautions
H302, H315, H319, H335
References & Citations
[1]Ito H, Ogata H, Yamamoto M, Takahashi K, Shishido K, Takahashi J, Taguchi S, Kinugasa E. Comparison of oral falecalcitriol and intravenous calcitriol in hemodialysis patients with secondary hyperparathyroidism: a randomized, crossover trial. Clin Nephrol. 2009 Jun;71 (6) :660-8.|[2]Tokunaga M, Tamura M, Kabashima N, Serino R, Shibata T, Matsumoto M, Miyamoto T, Miyazaki M, Furuno Y, Takeuchi M, Abe H, Okazaki M, Otsuji Y. Falecalcitriol for conventional vitamin D therapy-resistant secondary hyperparathyroidism in a continuous ambulatory peritoneal dialysis patient. Clin Nephrol. 2008 May;69 (5) :393-4.|[3]Iwao Y, Yamaguchi Y, Fujii K, Toba Y, Asada M, Nagano N, Yamamoto H, Hyoma K, Yamada S, Hirano H, Tone Y, Ohtani H, Saika Y, Fujii R. Long-term suppressive effect of falecalcitriol on parathyroid hormone secretion in secondary hyperparathyroidism in hemodialysis patients.Clin Calcium. 2006 May;16 (5) :847-51.|[4]Morii H. Falecalcitriol as a new therapeutic agent for secondary hyperparathyroidismClin Calcium. 2005 Jan;15 (1) :29-33.|[5]Ohtsuka N, Urayama K. Pharmacological action and clinical effects of falecalcitriol, a highly potent derivative of active vitamin D3.Nihon Yakurigaku Zasshi. 2002 Dec;120 (6) :427-36.|[6]Jean-Pierre Bégué, Danièle Bonnet-Delpon.Recent advances (1995-2005) in fluorinated pharmaceuticals based on natural products. Journal of Fluorine Chemistry.Volume 127, Issue 8, August 2006, Pages 992-1012
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
Launched